Shares of Dianthus Therapeutics Inc. (DNTH) surged 7.86% on Thursday morning, following the company's third-quarter earnings report that beat analysts' expectations on the revenue front.

The biotechnology firm reported a quarterly adjusted loss of $0.72 per share, wider than the expected loss of $0.59 per share. However, revenue rose a staggering 135.1% year-over-year to $2.17 million, significantly higher than the consensus estimate of $648,500.

Despite the larger-than-expected loss, investors seemed to be encouraged by Dianthus Therapeutics' strong revenue growth, driving the stock higher. The company's shares have gained 182.8% so far this year, reflecting the market's confidence in its prospects.